{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T21:14:35Z","timestamp":1795295675969,"version":"4.10.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Tokyo","id":[{"id":"https:\/\/ror.org\/057zh3y96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Although neoadjuvant chemoimmunotherapy is promising for resectable stage II\u2013III non-small cell lung cancer (NSCLC), some patients do not proceed to surgery. We aimed to investigate the clinical course and outcomes of patients whose surgery was cancelled after neoadjuvant chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicentre study (CReGYT-04: Neo-Venus study) included patients with resectable clinical stage II\u2013III NSCLC who received nivolumab neoadjuvant chemotherapy (2023\u20132024). Clinical characteristics were compared between a surgery-cancelled group and surgery-performed group. In the surgery-cancelled group, the reasons for surgery cancellation, salvage treatments, and effects of immune-related adverse events (irAEs) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 126 patients, 11 (8.7%) did not undergo surgery. Compared with the surgery-performed group, the surgery-cancelled group had a heavier smoking history, a higher frequency of adjacent organ invasion, a greater proportion of squamous cell carcinoma histology, and more frequent Grade 3\u20134 irAEs. Reasons for cancelling surgery included disease progression (n\u2009=\u20096, 55%), patient refusal (n\u2009=\u20093, 27%), and irAEs (n\u2009=\u20092, 18%). Four (36%) patients received intensive salvage treatment (concurrent chemoradiotherapy, 3 patients; chemoimmunotherapy, 1 patient), whereas seven patients received best supportive care (n\u2009=\u20094) or less-intensive salvage treatment such as radiotherapy alone (n\u2009=\u20092) and docetaxel monotherapy (n\u2009=\u20091). Among the four patients in the surgery-cancelled group who developed Grade 3\u20134 irAEs, none received intensive salvage treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intensive salvage treatment was administered to 36% of patients whose surgery was cancelled after neoadjuvant chemoimmunotherapy. These findings highlight the importance of optimising patient selection and irAE management to preserve opportunities for curative-intent treatment when adopting neoadjuvant strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11748-026-02354-z","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:07:29Z","timestamp":1784117249000},"page":"1200-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-172X","authenticated-orcid":false,"given":"Takaki","family":"Akamine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Hayasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinkichi","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Haratake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Soh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Ohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the CReGYT group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuta","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Oiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyo","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Nakatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Tenpaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoshiro","family":"Takegahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomichi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kosai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Notsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Sakane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Hanawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihito","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhisa","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyasu","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiju","family":"Aokage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2354_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390:1756\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2311926.","journal-title":"N Engl J Med"},{"key":"2354_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"key":"2354_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393:741\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2502931.","journal-title":"N Engl J Med"},{"key":"2354_CR4","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389:1672\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2304875.","journal-title":"N Engl J Med"},{"key":"2354_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cas.16030","volume":"115","author":"T Mitsudomi","year":"2024","unstructured":"Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, et al. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816. Cancer Sci. 2024;115:540\u201354. https:\/\/doi.org\/10.1111\/cas.16030.","journal-title":"Cancer Sci"},{"issue":"Suppl","key":"2354_CR6","doi-asserted-by":"publisher","first-page":"S451","DOI":"10.21037\/jtd.2018.01.109","volume":"10","author":"J Yeh","year":"2018","unstructured":"Yeh J, Marrone KA, Forde PM. Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl):S451\u20139. https:\/\/doi.org\/10.21037\/jtd.2018.01.109.","journal-title":"J Thorac Dis"},{"key":"2354_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","volume":"19","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024;19:1373\u2013414. https:\/\/doi.org\/10.1016\/j.jtho.2024.06.010.","journal-title":"J Thorac Oncol"},{"key":"2354_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cllc.2023.08.017","volume":"24","author":"K Takada","year":"2023","unstructured":"Takada K, Takamori S, Brunetti L, Crucitti P, Cortellini A. Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2023;24:581-90.e5. https:\/\/doi.org\/10.1016\/j.cllc.2023.08.017.","journal-title":"Clin Lung Cancer"},{"key":"2354_CR9","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.athoracsur.2025.09.054","volume":"121","author":"K Nomura","year":"2025","unstructured":"Nomura K, Watanabe T, Takamori S, Hamada A, Suda K, Ito M, et al. Safety profile of neoadjuvant chemoimmunotherapy with nivolumab for patients with resectable non-small cell lung cancer in the real world (CReGYT-04 neo-Venus). Ann Thorac Surg. 2025;121:1338\u201346. https:\/\/doi.org\/10.1016\/j.athoracsur.2025.09.054.","journal-title":"Ann Thorac Surg"},{"key":"2354_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100930","volume":"7","author":"T Watanabe","year":"2026","unstructured":"Watanabe T, Nomura K, Takamori S, Tane S, Ohara S, Oiki H, et al. Preoperative immune-related adverse events in resectable NSCLC treated with neoadjuvant nivolumab plus chemotherapy: a multicenter retrospective analysis. JTO Clin Res Rep. 2026;7:100930. https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100930.","journal-title":"JTO Clin Res Rep"},{"key":"2354_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jtho.2023.06.002","volume":"18","author":"C Dickhoff","year":"2023","unstructured":"Dickhoff C, Heineman DJ, Bahce I, Senan S. Unresectable Stage III NSCLC can be reevaluated for resectability after initial treatment. J Thorac Oncol. 2023;18:1124\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2023.06.002.","journal-title":"J Thorac Oncol"},{"key":"2354_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100834","volume":"6","author":"S Raimann","year":"2025","unstructured":"Raimann S, Schar S, Hayoz S, Guckenberger M, Finazzi T, Opitz I, et al. Outcomes in patients with resectable Stage III NSCLC who did not have definitive surgery after neoadjuvant treatment\u2014a retrospective analysis of the SAKK trials 16\/96, 16\/00, 16\/01, 16\/08, and 16\/14: a brief report. JTO Clin Res Rep. 2025;6:100834. https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100834.","journal-title":"JTO Clin Res Rep"},{"key":"2354_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-99571-y","volume":"15","author":"Y Qi","year":"2025","unstructured":"Qi Y, Sun Y, Hu Y, Zhu H, Guo H. Clinical outcomes of conversion surgery following neoadjuvant chemoimmunotherapy in potentially resectable stage IIIA\/IIIB non-small cell lung. Sci Rep. 2025;15:18422. https:\/\/doi.org\/10.1038\/s41598-025-99571-y.","journal-title":"Sci Rep"},{"key":"2354_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2026.03.567","author":"Z Yang","year":"2026","unstructured":"Yang Z, Wang S, Ni J, Yu X, Ju M, Zhu L, et al. Surgery versus definitive radiotherapy after induction immunochemotherapy for stage II and III non\u2013small cell lung cancer: a multicenter, pragmatic analysis. J Thorac Cardiovasc Surg. 2026. https:\/\/doi.org\/10.1016\/j.jtcvs.2026.03.567.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2354_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncol"},{"key":"2354_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404:1240\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)01756-2.","journal-title":"Lancet"},{"key":"2354_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100949","volume":"7","author":"E Adib","year":"2026","unstructured":"Adib E, Nassar AH, Lee KN, Fusco F, Crowley F, Baena J, et al. Definitive radiotherapy with or without chemotherapy after planned neoadjuvant chemoimmunotherapy in stages II to III NSCLC: an international multicenter retrospective study. JTO Clin Res Rep. 2026;7:100949. https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100949.","journal-title":"JTO Clin Res Rep"}],"container-title":["General Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-026-02354-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11748-026-02354-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-026-02354-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T21:03:03Z","timestamp":1795294983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11748-026-02354-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1007\/s11748-026-02354-z","relation":{},"ISSN":["1863-6705","1863-6713"],"issn-type":[{"value":"1863-6705","type":"print"},{"value":"1863-6713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Nomura has received honoraria from AstraZeneca, Chugai Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., and manuscript fees from TAIHO PHARMACEUTICAL CO., LTD. and Nipponrinshosha Co., Ltd. Dr. Haratake has received honoraria from AstraZeneca, EliLilly Japan and MSD. Dr. Hamada has received research funding from AstraZeneca and Chugai Pharmaceuticals; honoraria from AstraZeneca, Chugai Pharmaceuticals, Ono Pharmaceuticals, Bristol-Myers Squibb, and ETHICON; and advisory fees from AstraZeneca and Chugai Pharmaceuticals. Dr. Soh has received honoraria for lectures from Chugai Pharmaceutical Co., Ltd., Medtronic, PLC., CSL Behring, Johnson & Johnson, Intuitive Surgical, Inc., Olympus Corporation, Asahi Kasei Medical Co., Ltd., MSD K.K., AstraZeneca K.K., and Hisamitsu Pharmaceutical Co., Inc., and research grants from Chugai Pharmaceutical Co., Ltd. for molecular oncology of lung cancer. The remaining authors declare no conflict of interest or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}